DBA Italia srl

04/08/2022

DBA baby team

10/03/2022

In this study - BioChain's tissue array
Role of Neural (N)-Cadherin in Breast Cancer Stemness and Dormancy in the Bone Microenvironment.

In this study - BioChain's tissue array
Role of Neural (N)-Cadherin in Breast Cancer Stemness and Dormancy in the Bone Microenvironment.
"Breast cancer (BrCa) patients experience recurrence 7–25 years after mastectomy. Dormant often home to the bone and, upon reactivation, lead to secondary lesions. We previously demonstrated that, in the bone marrow, dormant BrCa cells are located near the endosteal niche enriched in spindle-shaped N-cadherin-high Osteoblasts (SNOs), show a stem signature like the LT-HSCs and express high levels of Notch2. Here, we observed that Notch2High human BrCa MDA cells are also N-CadherinHigh. When injected in vivo, N-CadherinHigh MDA cells show lower aggressiveness, and higher ability to colonize the endosteal niche and to adhere to SNOs compared to N-CadherinLow MDA cells. These cells have features typical of cancer stem cells, displaying a gene signature similar to the HSCs. In contrast, N-cadherin has a negative role in mouse 4T1 cell stemness and HSC mimicry. In brief, our results identified a role of N-Cadherin in BrCa dormancy and stemness, also highlighting the differences between human and mouse cell lines" Read more: https://lnkd.in/gRQfGEiR Breastcancer.org Breast Cancer Research AID


https://www.linkedin.com/feed/update/urn:li:activity:6907427415853801472

10/03/2022

Change is a beautiful thing!
We have given a fresh, new look to our virtual home! We think you will love it! Take a look! Visit us now - https://www.biochain.com/

18/11/2021

-Valid for ChromoTek reagents, except Nano-Traps with 10, 200 and 400 reactions; Nano-Trap sizes 20 and 100 reactions included. When combining different products, the lowest-priced item will be free of charge for you. Not in combination with other discounts or test samples. Valid in Europe only. Void where prohibited.

Please provide promo code 3for2 on your order to take advantage of this offer.-

Per informazioni : [email protected]

20/10/2021

! GlycoSeLect Ltd è specializzata nello sviluppo e nella produzione di Recombinant Prokaryotic Lectins (RPLs). Gli RPL sono composti con la proprietà di riconoscere e legare specifiche strutture di Glicani presenti su glicoproteine e altre biomolecole glicosilate.

Possono quindi consentire il rilevamento, l'analisi, la separazione e la purificazione di strutture glicosilate in modo semplice, veloce ed efficiente.

A differenza delle tradizionali lectine vegetali ed eucariotiche, la produzione recombinante di RPL permette di fornire prodotti di alta qualità con prestazioni affidabili, riproducibili con maggiore specificità e affinità per i glicani.
Vengono quindi garantite rese più elevate e particolarmente adatte a separazioni e purificazioni su larga scala. !

https://glycoselect.com

Contattaci per maggiori informazioni [email protected]

08/06/2021

"New IVD Products alert"
SignalChem, a global leader in cell signaling and protein engineering, has developed an extensive portfolio of bioallergens from various animal, plant, mold, and food sources following strict manufacturing processes and stringent quality control and assurance systems. These products are intended for in vitro diagnosis and research studies.
To discuss your IVD project needs contact us at [email protected] or visit us at https://signalchem.com/product_category_page.php... for more information.
#

04/06/2021

"NEW PRODUCT ALERT"
Recombinant Llama VHH-Human IgG Nanobodies to study neutralization of SARS-CoV-2 and to detect the 2019nCoV spike Protein.
Our Nanobies have been tested and validated for their neutralization potential against wild type and various new SARS-CoV-2 variants.
To discuss your COVID-19 research needs, please contact us at [email protected] or visit www.signalchem.com for more information.

05/05/2021

https://lnkd.in/eeAq3Ek

04/03/2021

"Emergenza di nuove varianti Covid e resistenza alla neutralizzazione anticorpale ′′

Strategizing research around neutralizing antibodies-resistant SARS-CoV-2 mutants can expedite our efforts to counter the COVID19 pandemic.